Napredna pretraga

Pregled bibliografske jedinice broj: 551716

Diclofenac Encephalopathy, Liver and Gastrointestinal Lesions in Rat and Stable Gastric Pentadecapeptide BPC 157


Ilić, Spomenko; Drmić, Domagoj; Kolenc, Danijela; Čorić, Marijana; Brčić, Luka; Klicek, Robert; Radić, Božo; Sever, Marko; Đuzel, Viktor; Filipović, Marinko et al.
Diclofenac Encephalopathy, Liver and Gastrointestinal Lesions in Rat and Stable Gastric Pentadecapeptide BPC 157 // Abstracts of the ….. ; u: Gastroenterology 138 (2010) (5/S1) ; M1274, 2010. str. S-369 (poster, nije recenziran, sažetak, znanstveni)


Naslov
Diclofenac Encephalopathy, Liver and Gastrointestinal Lesions in Rat and Stable Gastric Pentadecapeptide BPC 157

Autori
Ilić, Spomenko ; Drmić, Domagoj ; Kolenc, Danijela ; Čorić, Marijana ; Brčić, Luka ; Klicek, Robert ; Radić, Božo ; Sever, Marko ; Đuzel, Viktor ; Filipović, Marinko ; Ivica, Mihovil ; Boban Blagaić, Alenka ; Anić, Tomislav ; Zoričić, Ivan ; Gjurašin, Miroslav ; Romić, Željko ; Džidić, Senka ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the ….. ; u: Gastroenterology 138 (2010) (5/S1) ; M1274 / - , 2010, S-369

Mjesto i datum
,

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
Diclofenac encephalopathy; liver; gastrointestinal lesions; BPC 157; rats

Sažetak
Combined diclofenac encephalopathy, liver and gastrointestinal lesions have not yet been established in rats. The stable gastric pentadecapeptide, BPC 157 (GEPPPGKPADDAGLV, MW 1419, efficient in inflammatory bowel disease trials (PL 14736) and various wound treatment, no toxicity reported) is an anti-ulcer peptide with hepatoprotective effects that may also affectmany central disturbances. Diclofenac (12.5mg/kg)was given intraperitoneally once daily for 3 subsequent days. BPC 157 (10μg/kg, 10ng/kg) was given either (i) intraperi-toneally immediately after diclofenac or (ii) per-orally in drinking water (0.16 μg/ml, 0.16 ng/ml) up until the end of the experiment. At 3 h following the last diclofenac challenge, we evidenced severe gastric, intestinal and liver lesions, increased bilirubin, AST, ALT serum values, liver weight, prolonged sedation/unconsciousness (after any diclofenac challenge) and finally (hepatic) encephalopathy (Fig.1, C (control) B (BPC 157)). Brain edema was particularly present in the cerebral cortex and cerebellum, more in white than in gray matter, damaged (balloonized) red neurons were particularly expressed in the cerebral cortex and cerebellar nuclei, Purkinje cells and less expressed in hippocampal neurons. This was consistently counteracted in diclofenac-rats that received BPC 157 (μg- or ng-regimen, intraperitoneally or per-orally). In conclusion, the successful counteraction of combined diclofenac encephalopathy, liver and gastrointestinal lesions by BPC 157 regimens means that besides inflammatory bowel disease, diclofenac toxicity may be a new domain for possible BPC 157 therapy.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Predrag Sikirić, )
108-1083570-3636 - Učinak BPC 157 na induciranu bilijarnu opstrukciju (Tomislav Anić, )
108-1083570-3643 - Kvantitativna analiza i prijenos slike u patologiji (Sven Seiwerth, )

Ustanove
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE